Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune Diagnostics, Splicing Research, and RNA-Targeted Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HNRNPC drug discovery and diagnostic development. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HNRNPC Recombinant Protein (C1/C2 Isoforms, WT and Mutant) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Full-length and RRM-domain truncations available. |
View HNRNPC Products |
| Gene Delivery | HNRNPC Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and rescue experiments. Compatible with Tet-On systems. |
View HNRNPC Products |
| Benchmark Ab | Anti-HNRNPC (Research Grade) Recombinant rabbit monoclonal. Suitable for WB, IP, and IHC validation. |
View HNRNPC Products |
| Validator | HNRNPC siRNA Set (3 unique sequences) For knockdown-mediated specificity verification. |
View HNRNPC Products |
| Related Target 1 | HNRNPA1 hnRNP paralog for cross-reactivity and selectivity screening panels. |
View HNRNPA1 Products |
| Related Target 2 | HNRNPK Downstream co-regulator; complementary member of the hnRNP splicing network. |
View HNRNPK Products |
| Related Target 3 | METTL3 Synergistic RNA m6A processing pathway (writer). |
View METTL3 Products |
| Related Target 4 | YTHDF1 m6A reader, cooperative translational regulation. |
View YTHDF1 Products |
| Related Target 5 | HNRNPM Parallel pathway member in mRNA processing and stability regulation. |
View HNRNPM Products |
| Related Target 6 | PTBP1 Competitive/alternative splicing factor for selectivity profiling. |
View PTBP1 Products |
Critical Assay Challenges and TarMart Solutions
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Paralog selectivity (vs HNRNPA1/HNRNPK/hnRNP family) | Human hnRNP panel proteins with >95% purity; sequence verified by mass spec. |
| RNA-binding displacement (EMSA/FP) | Full-length & RRM-domain constructs; tag-free options for native folding. |
| Autoantibody epitope mapping | C1/C2 isoform-specific proteins with verified N-terminal truncations. |
| Intracellular target engagement (RIP & splicing reporter) | High-titer Lentivirus (ORF) for stable expression in HEK293/HeLa. |
| Off-target RBP counter-screening | Homologous family panel (HNRNPA1, HNRNPM, PTBP1) available with matched purity. |
| Specificity verification / false positives | Validated siRNA included for knockdown verification in cell-based assays. |
| Lack of controls | Recombinant positive control antibodies included. |
Live HNRNPC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Drug Resistance Research
- ➤ Latest Splicing & RBP Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The HNRNPC target landscape is bifurcated between established autoimmune diagnostics and emerging therapeutic discovery. In systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD), anti-HNRNPC autoantibodies represent established serological biomarkers, driving sustained demand for high-fidelity diagnostic antigens. Concurrently, preclinical oncology programs are increasingly scrutinizing HNRNPC's role in alternative splicing regulation, tumor stemness maintenance, and chemoresistance (e.g., breast, glioblastoma, hepatocellular carcinoma). Overexpression of HNRNPC is intimately linked to tumor progression and metastasis. As first-generation RNA-targeted therapies (ASOs, molecular glues) progress toward target validation, the next wave of R&D is heavily targeting small molecule RNA-protein interaction (RPI) disruptors and PROTAC-mediated degradation to overcome the historic "undruggable" nature of intracellular splicing factors. The field is transitioning from correlation to causation, requiring rigorous biochemical assays to resolve isoform-specific functions and paralog-selective pharmacology. Key mutations (e.g., in MRD74, uncertain significance) provide genetic clues that may inform future therapeutic strategies.
Competitive Modality & Indication Snapshot
Current R&D activity clusters around five core modalities, each imposing distinct analytical requirements.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule RPI Inhibitor | AstraZeneca, Novartis (academic collaborations); Emerging Biotech | Solid Tumors (HCC, TNBC, GBM) | RNA EMSA & FP Assays (Need high-purity full-length protein with functional RRM domains) |
| Diagnostic Autoantibody Assay | EUROIMMUN, Thermo Fisher, Werfen | SLE, MCTD, RA | Epitope-specific isoform proteins (Need C1/C2 specific antigens) |
| PROTAC / Targeted Degradation | Arvinas, Cullgen; Preclinical innovators | Refractory Cancers / Glioblastoma | Degradation Validation (Need specific Abs and lentivirus for reporter cells) |
| Antisense Oligonucleotides (ASO) | Ionis Pharmaceuticals, Biogen | Neurodegeneration, Cancer | Splicing Reporter Cell Lines (Need lentiviral ORF delivery for rescue experiments) |
| Splice-Switching Oligonucleotides | Stoke Therapeutics, Roche | Genetic Diseases | Isoform-Specific Detection (Need knockdown validators and isoform-specific antibodies) |
Key Facts and Resources
- Target Identity: HNRNPC (UniProt P07910) confirms RRM domain as a key functional domain. Mutations with uncertain significance in MRD74 have been reported (VAR_089339, VAR_089340, VAR_089341).
- Quality Control: All proteins are >95% pure, endotoxin <1 EU/µg, sequence verified by mass spectrometry and SEC.
- Cross-Species Products: Human, mouse, and cynomolgus monkey homologs available for preclinical bridging studies.